MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy

Journal of Clinical Investigation

Volumn 123, Issue 5, 2013, Pages 2143-2154

  Halkein, Julie ^a   Tabruyn, Sebastien P ^a   Ricke Hoch, Melanie ^b   Haghikia, Arash ^b   Nguyen, Ngoc Quynh Nhu ^a   Scherr, Michaela ^b   Castermans, Karolien ^a   Malvaux, Ludovic ^a   Lambert, Vincent ^a,c   Thiry, Marc ^a   Sliwa, Karen ^d   Noel, Agnes ^a   Martial, Joseph A ^a   Hilfiker Kleiner, Denise ^b   Struman, Ingrid ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 4; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; MICRORNA; MICRORNA 146A; NEUROBLASTOMA RAS VIRAL ONCOGENE HOMOLOG; NOTCH1 RECEPTOR; PROLACTIN; STAT3 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISENSE THERAPY; ARTICLE; CELL METABOLISM; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENDOTHELIUM CELL; EXOSOME; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INACTIVATION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PERIPARTUM CARDIOMYOPATHY; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; BIOLOGICAL MARKERS; CARDIOMYOPATHIES; ENDOTHELIAL CELLS; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; PERIPARTUM PERIOD; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROLACTIN; RATS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84877116748     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64365     Document Type: Article

References (47)

1. Hilfiker-Kleiner D, Sliwa K, Drexler H. Peripartum cardiomyopathy: recent insights in its pathophysiology. Trends Cardiovasc Med. 2008;18(5):173-179.
2. Hilfiker-Kleiner D, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128(3):589-600.
3. Hilfiker-Kleiner D, et al. Recovery from postpartum cardiomyopathy in 2 patients by blocking prolactin release with bromocriptine. J Am Coll Cardiol. 2007;50(24):2354-2355.
4. Sliwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121(13):1465-1473.
5. Pan H, et al. Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Invest Ophthalmol Vis Sci. 2004;45(7):2413-2419.
6. Bentzien F, Struman I, Martini JF, Martial JA, Weiner RI. Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice. Cancer Res. 2001;61(19):7356-7362.
7. Nguyen NQ, et al. Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL. Mol Ther. 2007;15(12):2094-2100.
8. Lee SH, Kunz J, Lin SH, Yu-Lee LY. 16-kDa prolactin inhibits endothelial cell migration by downregulating the Ras-Tiam1-Rac1-Pak1 signaling pathway. Cancer Res. 2007;67(22):11045-11053.
9. D'Angelo G, Struman I, Martial JA, Weiner RI. Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin. Proc Natl Acad Sci U S A. 1995;92(14):6374-6378.
10. Tabruyn SP, Nguyen NQ, Cornet AM, Martial JA, Struman I. The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases. Mol Endocrinol. 2005;19(7):1932-1942.
11. Tabruyn SP, et al. The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB. Mol Endocrinol. 2003;17(9):1815-1823.
12. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-233.
13. Wang S, Olson EN. AngiomiRs - key regulators of angiogenesis. Curr Opin Genet Dev. 2009; 19(3):205-211.
14. Kuehbacher A, Urbich C, Dimmeler S. Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci. 2008;29(1):12-15.
15. van Rooij E, et al. A signature pattern of stressresponsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A. 2006;103(48):18255-18260.
16. Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res. 2008;79(4):562-570.
17. Mitchell PS, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513-10518.
18. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110(1):13-21.
19. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-659.
20. Mayoral RJ, Pipkin ME, Pachkov M, van Nimwegen E, Rao A, Monticelli S. MicroRNA-221-222 regulate the cell cycle in mast cells. J Immunol. 2009;182(1):433-445.
21. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006;103(33):12481-12486.
22. Tili E, et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol. 2007;179(8):5082-5089.
23. van Dongen S, Abreu-Goodger C, Enright AJ. Detecting microRNA binding and siRNA offtarget effects from expression data. Nat Methods. 2008;5(12):1023- 1025.
24. Horie T, et al. Acute doxorubicin cardiotoxicity is associated with miR-146a-induced inhibition of the neuregulin-ErbB pathway. Cardiovasc Res. 2010;87(4):656-664.
25. Keene JD, Komisarow JM, Friedersdorf MB. RIP-Chip: the isolation and identification of mRNAs, microRNAs and protein components of ribonu-cleoprotein complexes from cell extracts. Nat Protoc. 2006;1(1):302-307.
26. Mei J, Bachoo R, Zhang CL. MicroRNA-146a inhibits glioma development by targeting Notch1. Mol Cell Biol. 2011;31(17):3584-3592.
27. Odiete O, Hill MF, Sawyer DB. Neuregulin in cardiovascular development and disease. Circ Res. 2012;111(10):1376-1385.
28. Bonauer A, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324(5935):1710-1713.
29. Patten IS, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485(7398):333-338.
30. Corbacho AM, Martinez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol. 2002;173(2):219-238.
31. Shapiro P. Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy. Crit Rev Clin Lab Sci. 2002;39(4-5):285-330.
32. Kosaka N, Iguchi H, Ochiya T. Circulating micro-RNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101(10):2087-2092.
33. Ozcelik C, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc Natl Acad Sci U S A. 2002;99(13):8880-8885.
34. Pentassuglia L, Sawyer DB. The role of Neuregulin-1beta/ErbB signaling in the heart. Exp Cell Res. 2009;315(4):627-637.
35. Lemmens K, Doggen K, De Keulenaer GW. Activation of the neuregulin/ErbB system during physiological ventricular remodeling in pregnancy. Am J Physiol Heart Circ Physiol. 2011;300(3):H931-H942.
36. Lemmens K, Segers VF, Demolder M, De Keulenaer GW. Role of neuregulin-1/ErbB2 signaling in endothelium-cardiomyocyte cross-talk. J Biol Chem. 2006;281(28):19469-19477.
37. Hedhli N, et al. Endothelium-derived neuregulin protects the heart against ischemic injury. Circulation. 2011;123(20):2254-2262.
38. Tabruyn SP, et al. NF-kappaB activation in endothelial cells is critical for the activity of angiostatic agents. Mol Cancer Ther. 2009;8(9):2645-2654.
39. Hilfiker-Kleiner D, et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res. 2004;95(2):187-195.
40. Haghikia A, et al. Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. Eur Heart J. 2011;32(10):1287-1297.
41. Struman I, et al. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci U S A. 1999;96(4):1246-1251.
42. Boon RA, et al. MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ Res. 2011;109(10):1115-1119.
43. Hilfiker-Kleiner D, et al. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation. 2010;122(2):145-155.
44. Hilfiker-Kleiner D, et al. Lack of JunD promotes pressure overload-induced apoptosis, hypertrophic growth, and angiogenesis in the heart. Circulation. 2005;112(10):1470-1477.
45. Sabatel C, et al. MicroRNA-21 exhibits antiangio-genic function by targeting RhoB expression in endothelial cells. PLoS One. 2011;6(2):e16979.
46. Berndt S, et al. Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium. FASEB J. 2006;20(14):2630-2632.
47. Lambert V, et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J. 2001;15(6):1021-1027.